Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats

Area of Science:

• Urology
• Pharmacology
• Biochemistry

Background:

• Benign prostatic hyperplasia (BPH) is a common urologic condition in aging males, influenced by oxidative stress and inflammation.
• Berberine (BBR), a natural compound, possesses known antioxidant and anti-inflammatory properties.
• Investigating BBR's therapeutic potential for BPH is crucial given its prevalence.

Purpose of the Study:

• To evaluate the efficacy of Berberine (BBR) in mitigating testosterone-induced benign prostatic hyperplasia (BPH) in a rat model.
• To assess the impact of BBR on key biochemical markers associated with BPH development.

Main Methods:

• Rats were induced with BPH using testosterone and treated with varying doses of BBR or finasteride.
• Serum hormone levels (testosterone, dihydrotestosterone) were measured.
• Prostate tissues were analyzed for oxidative stress markers, inflammation, and histopathological changes.

Main Results:

• BBR administration significantly prevented elevated serum testosterone and dihydrotestosterone levels.
• BBR treatment reduced BPH-induced oxidative stress by decreasing lipid peroxidation and nitrite levels.
• BBR suppressed pro-inflammatory cytokines (IL-1β, TNF-α) and preserved antioxidant enzymes (GSH, catalase, SOD), improving prostate histology.

Conclusions:

• Berberine (BBR) demonstrates significant efficacy in preventing the development of testosterone-stimulated benign prostatic hyperplasia (BPH) in rats.
• BBR's antioxidant and anti-inflammatory actions contribute to its protective effects against BPH.
• These findings suggest BBR as a potential therapeutic agent for managing BPH.